Jacqueline Mercier is a partner in the firm’s Business Law Department and a member of Goodwin’s Technology and Life Sciences groups and a member of the Goodwin Life Sciences and Public Company Advisory practices. Ms. Mercier focuses her practice on late-stage and publicly traded company representation, including in matters related to corporate governance, mergers and acquisitions, royalty-based financings and other complex transactions, securities offerings, securities law compliance, proxy contests and general corporate matters. Ms. Mercier originally joined Goodwin in 2007.





Recent representative transactional matters include:

  • Royalty Pharma’s purchase of certain revenue streams from Biocryst Pharmaceuticals
  • Vigil Neuroscience in its $90 million Series B financing 
  • Royalty Pharma’s purchase of MorphoSys’ rights to receive future royalties on Janssen’s Tremfya in connection with a $2 billion strategic funding partnership as part of MorphoSys’ acquisition of Constellation Pharmaceuticals
  • Royalty Pharma’s purchase of certain royalty interests from GlaxoSmithKline
  • Sale of Cadent Therapeutics to Novartis
  • Royalty Pharma’s purchase of certain royalty streams from BioHaven Pharmaceuticals
  • Sale of AMAG Pharmaceuticals to Covis Pharma, an Apollo Global Management company
  • Royalty Pharma’s purchase of certain royalty rights from PTC Therapeutics
  • Royalty Pharma’s purchase of certain royalty rights from Ultragenyx Pharmaceutical
  • AMAG Pharmaceuticals in the divestiture of its Intrarosa business line
  • Wayfair in its $535 million private placement of convertible senior notes
  • Novelion Therapeutics in its business combination with Amryt Pharma plc
  • Centerbridge Partners in its acquisition of Civitas Solutions
  • Keryx Biopharmaceuticals in its merger with Akebia Therapeutics
  • GLPI in its purchase of Tropicana Entertainment casinos
  • Cascadian Therapeutics in its sale to Seattle Genetics
  • Citrix in its $2.6 billion Reverse Morris Trust merger with LogMeIn 
  • First Eagle in its purchase of Newstar Financial
  • Cornerstone OnDemand in its $300 million strategic investment led by Silver Lake 
  • Lionbridge in its sale to HIG 
  • Teva in its acquisition of Auspex Pharmaceuticals
  • Centerview Partners in connection with the sale of Pharmacyclics to AbbVie
  • Trulia in its sale to Zillow
  • Courier Corporation in its sale to R.R. Donnelley
  • Citrix’s $1.4 billion convertible notes offering
  • Mac-Gray Corporation in its sale to CSC ServiceWorks, Inc.
  • athenahealth in its acquisition of Epocrates, Inc.
  • Avila Therapeutics in its sale to Celgene Corporation

Ms. Mercier has also provided ongoing corporate governance and securities law advice to many of the firm’s late stage and public company clients, including Alkermes, Altos Labs, Amarin Corporation, AMAG Pharmaceuticals, Citrix Systems, Juvenescence, Kymera Therapeutics, Lionbridge Technologies, Novelion Therapeutics, Oxford Immunotec, Rubius Therapeutics, Vericel Corporation, Vigil Neuroscience and Zalicus.

Professional Activities

Ms. Mercier is a member of the Massachusetts and Boston Bar Associations.

Professional Experience
Ms. Mercier rejoined Goodwin in 2012 after serving as senior corporate counsel at Citrix where she worked on several strategic acquisitions and on Citrix’s corporate governance and securities matters. Prior to attending law school, Ms. Mercier was CFO and Controller of Louis, Inc. in Boston, Massachusetts.


Ms. Mercier has been selected for inclusion in The Legal 500 U.S. 2022. She was named an Acritas Star for 2019. The annual global report honors lawyers who exemplify professional excellence, innovation, and collaboration in the legal profession, and is based on over 6,500 interviews with clients around the world.

While attending law school, Ms. Mercier was the Note Editor of the Boston College Third World Law Journal for which she wrote “Eliminating Child Marriage in India: A Backdoor Approach to Alleviating Human Rights Violations” (Winter 2006).

Upon graduating from law school, Ms. Mercier was the recipient of the Richard G. Huber Award for her scholarship and leadership in extra and co-curricular activities.

In The News









JD, 2007
Boston College Law School
BS, 2000
Boston College



Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.


Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Search Other Lawyers
Recherche par Pratique